Sudeep Pharma ipo date, Share Price Target Tomorrow, 2025, 2026, 2030
Sudeep Pharma makes mineral-based ingredients used in medicines, food items, and health supplements. It makes helpful materials like calcium, iron, magnesium, zinc, potassium, and sodium salts, and offers more than 100 products used by pharma and nutrition companies. The company uses modern methods like spray drying, granulation, encapsulation, and liposomal technology to make its products better and more effective. Its factories are in Vadodara, Gujarat, and some of them have international approvals like USFDA clearance. At present, it supplies its products to over 1,100 customers in more than 100 countries, including big names like Pfizer, Merck Group, and Danone.
- 1 What is Sudeep Pharma Ltd IPO?
- 2 Sudeep Pharma IPO Details
- 3 Sudeep Pharma Share Price Target Tomorrow (Listing day price)
- 4 Sudeep Pharma Share Price Target 2025
- 5 Sudeep Pharma share price Target 2026
- 6 Share price Target 2027
- 7 Share price Target 2028
- 8 Share price Target 2029
- 9 Sudeep Pharma share price Target 2030
- 10 Share price Target 2040
- 11 Share Price Target 2050
- 12 Should I buy Sudeep Pharma stock?
- 13 Sudeep Pharma earnings results (Financials)
- 14 Is Sudeep Pharma stock good to buy? (bull case & bear case)
- 15 Sudeep Pharma IPO Promoter Holding
- 16 Objects of the Issue (Sudeep Pharma IPO Objectives)
- 17 Sudeep Pharma ipo gmp
- 18 Conclusion
- 19 FAQs
What is Sudeep Pharma Ltd IPO?
Sudeep Pharma was established in 1989 in Vadodara, Gujarat, by Sujit Bhayani. It is an Indian company that makes simple mineral-based ingredients used in medicines, health supplements, and some food products. It makes useful materials like calcium, iron, zinc, and magnesium that are used in making tablets, syrups, and capsules. The company has three modern factories, works with more than 1,100 customers worldwide, and supplies big companies like Pfizer, Merck, Danone, and Intas. It also has offices in Europe and the US to support its international business.
Sudeep Pharma IPO Details
| IPO Date | November 21, 2025 to November 25, 2025 |
| Listing Date | 26 Nov 2025 |
| Face Value | ₹1 per share |
| Price Band | ₹563 to ₹593 per share |
| Minimum Investment | ₹14075 |
| Lot Size | 25 Shares |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 11,13,46,602 shares |
| Share Holding Post Issue | 11,29,48,626 shares |
The company earns good returns, it uses its money well and runs its business smoothly. Its profit margins have improved, showing better control over costs and stronger performance. Even though it has taken some loans to expand, it still brings in steady cash and has built strong reserves, which is a positive sign. Overall, the company looks financially healthy and growing, but it needs to manage its debt and high inventory levels carefully to stay safe in the long run.
| Day | Minimum Price (Rs) | Maximum Price (Rs) |
| Tomorrow | -67 | +168 |
The company started in 1989 in Vadodara, Gujarat, to make high-quality mineral ingredients for medicines and nutrition products. Over the years, the company has grown into a trusted name in the global pharmaceutical and food industries. It slowly gained knowledge, expanded its product range, and improved its technology. Today, it is known for using science to make pure products and having reliable manufacturing systems. Its long history shows stability, experience, and the ability to meet the needs of customers in different countries and industries. In 2025, its share price target would be ₹830, as per stock market analysts.
Its share price would be between ₹474 to ₹830 in 2025, as per stock market analysts.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 474 | 830 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| November | 474 | 690 |
| December | 500 | 830 |
It offers over 100 products, making it one of the most diverse companies in the mineral ingredient field. These products include pharmaceutical excipients, food-grade minerals, speciality mineral salts, vitamin and mineral mixes, and customised blends for nutrition companies. Each type has a specific use. For example, excipients help tablets stay strong and stable, while premixes are used in infant food, health drinks, and dietary supplements. The company serve different industries and meets the unique needs of each customer. In 2026, its share price target would be ₹1500, as per stock market analysts.
Its share price would be between ₹800 to ₹1500 in 2026, as per stock market analysts.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2026 | 800 | 1500 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 800 | 1020 |
| February | 910 | 1074 |
| March | 924 | 1121 |
| April | 953 | 1154 |
| May | 1025 | 1170 |
| June | 1074 | 1221 |
| July | 1110 | 1290 |
| August | 1132 | 1332 |
| September | 1184 | 1375 |
| October | 1250 | 1410 |
| November | 1289 | 1474 |
| December | 1374 | 1500 |
The company uses modern technology to make its mineral ingredients. Some important processes are spray drying, granulation, encapsulation, micronisation, blending, and liposomal technology. These processes help improve the quality, texture, release, and stability of minerals. For example, encapsulation allows minerals to release slowly in the body, making them more effective, while spray drying creates powders that dissolve easily. It keeps products consistent and meets the needs of pharmaceutical and nutrition companies around the world. In 2027, its share price target would be ₹1950, as per stock market analysts.
Its share price would be between ₹1444 to ₹1950 in 2027, as per stock market analysts.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2027 | 1444 | 1950 |
One important step was buying Nutrition Supplies Services (NSS), a European company that makes special nutrient mixes. This helped the company to grow its nutrition business and make better products for babies, medical use, and health supplements. With NSS’s mix of skills, the company reach more customers in different countries. The company focuses on growing, improving its products, and serving customers in a simple and better way. In 2028, its share price target would be ₹, as per stock market analysts.
Its share price would be between ₹ to ₹ in 2028, as per stock market analysts.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2028 | 1874 | 2474 |
The company has a strong research and development (R&D) team that works on improving mineral products, creating new types, and making customised solutions for clients. R&D helps minerals be absorbed better in the body and improves their quality for medicines. The team also works closely with customers to create special solutions for unique needs. So it helps the company to stay ahead of competitors and meet modern market demands, making it a trusted partner for many pharmaceutical and nutrition companies worldwide. In 2029, its share price target would be ₹3024, as per stock market analysts.
Its share price would be between ₹2442 to ₹3024 in 2029, as per stock market analysts.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2029 | 2442 | 3024 |
It has several manufacturing facilities in Vadodara, Gujarat. These factories have modern machines, automated systems, and strict quality checks. They can produce large amounts while keeping products pure and consistent. The company invests regularly to upgrade equipment, expand production lines, and improve processes to meet growing demand. Each facility follows global standards and is inspected regularly. In 2030, its share price target would be ₹3665, as per stock market analysts.
Its share price would be between ₹2974 to ₹3665 in 2030, as per stock market analysts.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2030 | 2974 | 3665 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 2974 | 3112 |
| February | 2990 | 3175 |
| March | 3020 | 3210 |
| April | 3068 | 3274 |
| May | 3085 | 3325 |
| June | 3110 | 3374 |
| July | 3156 | 3441 |
| August | 3182 | 3478 |
| September | 3225 | 3537 |
| October | 3327 | 3588 |
| November | 3378 | 3614 |
| December | 3414 | 3665 |
The company serves over 1,100 clients worldwide, including well-known pharmaceutical companies like Pfizer and Merck, and nutrition brands like Danone. The company is trusted for quality and reliability. Many clients have long-term relationships with Sudeep Pharma because they value consistent quality, technical support, and the company’s ability to meet strict standards. A large customer base helps the company grow steadily and reduces business risks. In 2040, its share price target would be ₹6425, as per stock market analysts.
Its share price would be between ₹5740 to ₹6425 in 2040, as per stock market analysts.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2040 | 5740 | 6425 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 5740 | 5884 |
| February | 5821 | 5936 |
| March | 5850 | 5974 |
| April | 5885 | 6041 |
| May | 5961 | 6080 |
| June | 5980 | 6114 |
| July | 6032 | 6175 |
| August | 6074 | 6223 |
| September | 6124 | 6268 |
| October | 6175 | 6290 |
| November | 6254 | 6334 |
| December | 6280 | 6425 |
It has a strong supply chain that allows it to deliver products around the world on time. Its system includes storage facilities, export teams, logistics partners, and international offices. This ensures that products reach customers safely and quickly. The company also provides technical documents, regulatory support, and product information. A strong supply chain is very important for global business, and it has built a system that supports long-term growth and customer satisfaction. In 2050, its share price target would be ₹11740, as per stock market analysts.
Its share price would be between ₹10851 to ₹11740 in 2050, as per stock market analysts.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2050 | 10851 | 11740 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 10851 | 10990 |
| February | 10884 | 11075 |
| March | 10935 | 11132 |
| April | 10972 | 11185 |
| May | 11058 | 11245 |
| June | 11090 | 11287 |
| July | 11153 | 11335 |
| August | 11210 | 11395 |
| September | 11275 | 11425 |
| October | 11335 | 11562 |
| November | 11452 | 11632 |
| December | 11558 | 11740 |
Should I buy Sudeep Pharma stock?
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 474 | 830 |
| 2026 | 800 | 1500 |
| 2027 | 1444 | 1950 |
| 2028 | 1874 | 2474 |
| 2029 | 2442 | 3024 |
| 2030 | 2974 | 3665 |
| 2040 | 5740 | 6425 |
| 2050 | 10851 | 11740 |
It makes important mineral ingredients used in medicines and nutrition products, and has many customers worldwide. The company has strong research, modern factories, and high-quality products, which help it grow. It has also expanded by buying other companies and reaching global markets. However, there are some risks, like depending on a few big customers, selling a lot to other countries, and using new machines properly. Overall, it is a strong company, but it is safer to start with a small investment and see how it grows.
Sudeep Pharma earnings results (Financials)
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | |
| Sales + | 123 | 215 | 343 | 459 | 502 |
| Expenses + | 98 | 171 | 276 | 277 | 311 |
| Operating Profit | 25 | 44 | 67 | 182 | 191 |
| OPM % | 21% | 20% | 20% | 40% | 38% |
| Other Income + | 3 | 3 | 7 | 6 | 9 |
| Interest | 1 | 1 | 2 | 5 | 7 |
| Depreciation | 3 | 4 | 5 | 9 | 11 |
| Profit before tax | 25 | 43 | 69 | 175 | 183 |
| Tax % | 27% | 22% | 27% | 24% | 24% |
| Net Profit + | 18 | 33 | 50 | 133 | 139 |
| EPS in Rs | |||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Is Sudeep Pharma stock good to buy? (bull case & bear case)
Bull Case:
- In FY25, the company earned ₹502.00 crore, up from ₹459.28 crore in FY24, showing it is growing and operating on a large scale.
- Its profit after tax (PAT) increased to ₹138.69 crore in FY25, compared to ₹133.15 crore in FY24, which means it is earning more and managing costs better.
- The company’s EBITDA went up from ₹98.64 crore in FY23 to ₹199.28 crore in FY25, showing it is becoming more efficient in its operations.
- It has low debt, meaning it does not have heavy loans and is financially stable.
- It has three manufacturing plants in Vadodara, Gujarat, helping it produce more products and reach customers faster.
- The company serves over 1,100 customers worldwide, including big brands like Pfizer, Merck, and Danone, which shows it is trusted globally.
Bear Case:
- A large part of the revenue comes from a few big customers. Losing one of them could affect earnings significantly.
- The company depends on raw materials like minerals, so any rise in prices or shortage could reduce profits.
- Plans to expand manufacturing capacity with new machines carry risk; if demand does not grow, the investment may not pay off.
- Regulatory risk is high because the company works in pharmaceutical and nutritional ingredients. Any failure in quality checks or approvals could hurt the business.
Sudeep Pharma IPO Promoter Holding
Sujit Jaysukh Bhayani, Avani Sujit Bhayani, Shanil Sujit Bhayani, Sujeet Jaysukh Bhayani HUF, Riva Resources Private Limited, and Bhayani Family Trust are the promoters of the company.
| Promoter Holding Pre Issue | 89.37% |
| Promoter Holding Post Issue | 76.15% |
Objects of the Issue (Sudeep Pharma IPO Objectives)
- ₹75.81 crore will be used to buy new machinery for the production line at the Nandesari Facility to increase production capacity.
- The rest will be used for the company’s general corporate purposes.
Sudeep Pharma ipo gmp
| GMP Date | IPO Price | GMP | Sub2 Sauda Rate | Estimated Listing Price | Estimated Profit* | Last Updated |
| 19-11-2025 | 593.00 | ₹135 | 2600/36400 | ₹728 (22.77%) | ₹3375 | 19-Nov-2025 |
| 18-11-2025 | 593.00 | ₹93 | 1800/25200 | ₹686 (15.68%) | ₹2325 | 18-Nov-2025 |
| 17-11-2025 | ₹0 | — | ₹ (%) | — | 17-Nov-2025 |
Conclusion
It is a growing company that makes important minerals used in medicines, health supplements, and some foods. It has more than 100 products, such as calcium, iron, magnesium, zinc, potassium, and sodium, and works with over 1,100 customers worldwide, including big companies like Pfizer, Merck, and Danone. The company uses modern methods like spray drying, granulation, and encapsulation to make its products high-quality and effective. Even though it has some risks, like depending on a few big customers and changes in raw material prices, it is a strong and reliable company in the medicine and nutrition business.
